Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an Fc?RIIA polymorphism, or an Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and an Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.
Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.
Abstract: Methods and materials are provided for selecting and/or treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIB polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIB polymorphism, for treatment with a therapy including an antibody therapy such as rituximab. Methods are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIB polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIB polymorphism.
Abstract: The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.
Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.